Physician profile
Jane A Crick
NPI 1639269368
$1,487.65
in general payments reported to CMS, 2019-2025
30 companies · $411 in 2025
The $411 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $169 · 2020: $30.22 · 2022: $12.57 · 2023: $439 · 2024: $425 · 2025: $411.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,254 · Education: $21.68.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,253.97 |
| Education | $21.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $247.56 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $197.65 | 2019-2025 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $178.57 | 2023-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $89.47 | 2019-2025 | |
| Exact Sciences Corporation | $75.81 | 2023-2024 | Cologuard Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $71.41 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Phathom Pharmaceuticals, INC. | $65.53 | 2024-2025 | Voquezna |
| Abbvie INC. | $51.94 | 2019-2020 | |
| Abbott Laboratories | $49.07 | 2023 | Freestyle Libre 3 |
| Glaxosmithkline, LLC. | $44.04 | 2019-2024 | Shingrix, Arexvy |
| Corcept Therapeutics | $39.99 | 2024 | Korlym |
| Dexcom, INC. | $36.68 | 2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.45 | 2019-2025 | Jardiance |
| Aimmune Therapeutics, INC. | $33.09 | 2025 | Vowst |
| Xeris Pharmaceuticals, INC. | $24.08 | 2025 | Keveyis |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $22.98 | 2025 | |
| Opko Pharmaceuticals, LLC | $21.68 | 2025 | Rayaldee |
| Sanofi-Aventis U.S. LLC | $20.86 | 2024 | |
| Genentech USA, INC. | $20.62 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.10 | 2024 | |
| Sumitomo Pharma America, INC. | $16.96 | 2025 | Gemtesa |
| Hologic Sales and Service, LLC | $16.65 | 2025 | Aptima |
| Otsuka America Pharmaceutical, INC. | $16.49 | 2023 | Rexulti |
| Watermark Medical, INC. | $15.09 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $14.90 | 2025 | Zoryve |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.24 | 2024 | Xifaxan |
| Amgen INC. | $13.38 | 2023 | Otezla, Repatha |
| Medtronic, INC. | $12.57 | 2022 | |
| Merck Sharp & Dohme LLC | $12.15 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Crick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.